ARS Pharmaceuticals, Inc (SPRY) - Total Liabilities
Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) has total liabilities worth $213.39 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ARS Pharmaceuticals, Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
ARS Pharmaceuticals, Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how ARS Pharmaceuticals, Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ARS Pharmaceuticals, Inc balance sheet assets.
ARS Pharmaceuticals, Inc Competitors by Total Liabilities
The table below lists competitors of ARS Pharmaceuticals, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Norma Group AG NA O.N.
XETRA:NOEJ
|
Germany | €713.83 Million |
|
Yunnan Yuntou Ecology and Environment Technology Co Ltd
SHE:002200
|
China | CN¥1.31 Billion |
|
Focus Hotmelt Co. Ltd. A
SHE:301283
|
China | CN¥914.00 Million |
|
IGG Inc
F:I91
|
Germany | €1.18 Billion |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
USA | $94.61 Million |
|
Volatus Aerospace Inc
V:FLT
|
Canada | CA$26.80 Million |
|
Hunan Sokan New Materials Co. Ltd. A
SHG:688157
|
China | CN¥336.31 Million |
|
SNT Motiv Co Ltd
KO:064960
|
Korea | ₩259.97 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down ARS Pharmaceuticals, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ARS Pharmaceuticals, Inc (SPRY) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ARS Pharmaceuticals, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ARS Pharmaceuticals, Inc (2018–2025)
The table below shows the annual total liabilities of ARS Pharmaceuticals, Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $213.39 Million | +126.16% |
| 2024-12-31 | $94.36 Million | +3786.12% |
| 2023-12-31 | $2.43 Million | -71.60% |
| 2022-12-31 | $8.55 Million | -90.78% |
| 2021-12-31 | $92.72 Million | +129.16% |
| 2020-12-31 | $40.46 Million | +90.40% |
| 2019-12-31 | $21.25 Million | +127.27% |
| 2018-12-31 | $9.35 Million | -- |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more